Ota K, Kimura T, Sakurada T, Shoji M, Inoue M, Sato K, Ohta M, Yamamoto T, Funyu T, Yoshida K
Second Department of Internal Medicine, Tohoku University School of Medicine, Sendai, Japan.
Endocr J. 1994 Feb;41(1):99-105. doi: 10.1507/endocrj.41.99.
To assess whether atrial natriuretic peptide (ANP) and arginine vasopressin (AVP) participate in impaired water excretion in patients with hypothyroid states (HS), an oral acute water loading (WL) test (20 ml/kg.BW/45 min) was performed before and after L-thyroxine (T4) treatment in 5 hypothyroid patients. Plasma ANP, AVP, osmolality (Posm), total protein and renal water excretion were simultaneously determined, and these data were compared to the data from five normal subjects (NS). The impaired water excretion rate in HS was entirely improved in the euthyroid states (ES) after T4 therapy for at least 7 months. Plasma ANP in HS was lower than that in NS (5.9 +/- 0.9 vs. 16.5 +/- 3.6 pmol/L, P < 0.05), but increased after T4 treatment (21.2 +/- 5.7 pmol/L, P < 0.05). Plasma AVP in HS (1.6 +/- 0.5 pmol/L) showed a tendency to be lower than those in ES and NS (2.9 +/- 0.4 and 2.9 +/- 0.7 pmol/L), but did not respond to a fall in Posm after WL, unlike ES and NS. Significant positive correlations were noticed between Posm and plasma AVP in ES and NS, but not in HS. These results suggest that not only the impaired release and/or metabolisms of AVP and ANP, but also derangement of renal water and electrolytes handling might induce attenuation of CH2O formation in hypothyroid states.
为评估心房利钠肽(ANP)和精氨酸加压素(AVP)是否参与甲状腺功能减退状态(HS)患者水排泄受损,对5例甲状腺功能减退患者在左甲状腺素(T4)治疗前后进行了口服急性水负荷(WL)试验(20 ml/kg体重/45分钟)。同时测定血浆ANP、AVP、渗透压(Posm)、总蛋白和肾脏水排泄,并将这些数据与5名正常受试者(NS)的数据进行比较。在T4治疗至少7个月后,甲状腺功能正常状态(ES)下HS患者受损的水排泄率完全得到改善。HS患者血浆ANP低于NS患者(5.9±0.9对16.5±3.6 pmol/L,P<0.05),但T4治疗后升高(至21.2±5.7 pmol/L,P<0.05)。HS患者血浆AVP(1.6±0.5 pmol/L)有低于ES患者和NS患者(分别为2.9±0.4和2.9±0.7 pmol/L)的趋势,但与ES患者和NS患者不同,WL后对Posm下降无反应。在ES患者和NS患者中,Posm与血浆AVP之间存在显著正相关,而在HS患者中未观察到。这些结果表明,不仅AVP和ANP的释放和/或代谢受损,而且肾脏对水和电解质的处理紊乱可能导致甲状腺功能减退状态下CH2O生成减弱。